心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2021 EAS共识声明：富含甘油三酯的脂蛋白及其残余物—代谢观察，在动脉硬化性心血管疾病中的作用及新兴治疗策略

2021-09-02 欧洲动脉硬化学会 Eur Heart J

富含甘油三酯的脂蛋白

2021年9月，欧洲动脉硬化学会(EAS)发布了关于富含甘油三酯的脂蛋白及其残余物—代谢观察，在动脉硬化性心血管疾病中的作用及新兴治疗策略的共识声明。

中文标题：

2021 EAS共识声明：富含甘油三酯的脂蛋白及其残余物—代谢观察，在动脉硬化性心血管疾病中的作用及新兴治疗策略

英文标题：

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society

发布机构：

欧洲动脉硬化学会

发布日期：

2021-09-02

简要介绍：

2021年9月，欧洲动脉硬化学会(EAS)发布了关于富含甘油三酯的脂蛋白及其残余物—代谢观察，在动脉硬化性心血管疾病中的作用及新兴治疗策略的共识声明。本文批判性地评价了当前关于富含甘油三酯的脂蛋白（TRL）的结构、功能和代谢的理解，以及TRL在动脉硬化性心血管疾病中的作用。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 EAS共识声明：富含甘油三酯的脂蛋白及其残余物—代谢观察，在动脉硬化性心血管疾病中的作用及新兴治疗策略.pdf)] GetToolGuiderByIdResponse(projectId=1, id=a2d711c0022215d3, title=2021 EAS共识声明：富含甘油三酯的脂蛋白及其残余物—代谢观察，在动脉硬化性心血管疾病中的作用及新兴治疗策略, enTitle=Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society, guiderFrom=Eur Heart J, authorId=0, author=, summary=2021年9月，欧洲动脉硬化学会(EAS)发布了关于富含甘油三酯的脂蛋白及其残余物&mdash;代谢观察，在动脉硬化性心血管疾病中的作用及新兴治疗策略的共识声明。, cover=https://img.medsci.cn/20211021/1634791877742_5579292.jpg, journalId=0, articlesId=null, associationId=64, associationName=欧洲动脉硬化学会, associationIntro=null, copyright=0, guiderPublishedTime=Thu Sep 02 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年9月，欧洲动脉硬化学会(EAS)发布了关于富含甘油三酯的脂蛋白及其残余物&mdash;代谢观察，在动脉硬化性心血管疾病中的作用及新兴治疗策略的共识声明。本文批判性地评价了当前关于富含甘油三酯的脂蛋白（TRL）的结构、功能和代谢的理解，以及TRL在动脉硬化性心血管疾病中的作用。</span></p>, tagList=[TagDto(tagId=116276, tagName=富含甘油三酯的脂蛋白)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1750, guiderKeyword=动脉硬化, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2912, appHits=84, showAppHits=0, pcHits=390, showPcHits=2828, likes=1, shares=2, comments=3, approvalStatus=1, publishedTime=Thu Oct 21 13:03:23 CST 2021, publishedTimeString=2021-09-02, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Thu Oct 21 12:55:31 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 21:40:47 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 EAS共识声明：富含甘油三酯的脂蛋白及其残余物—代谢观察，在动脉硬化性心血管疾病中的作用及新兴治疗策略.pdf)])
2021 EAS共识声明：富含甘油三酯的脂蛋白及其残余物—代谢观察，在动脉硬化性心血管疾病中的作用及新兴治疗策略.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1074224, encodeId=cfc210e42247a, content=不错 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:13:29 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062953, encodeId=009110629531e, content=非常值得一看，，特别有意思, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=LFRRP6YqrAia0BryFmv6ibnA&s=100&t=1555426989, createdBy=79c45230339, createdName=刘晓捷, createdTime=Fri Oct 22 14:49:27 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062735, encodeId=77601062e35a1, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Oct 21 21:17:57 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
    2021-11-26 H8888888

    不错 学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1074224, encodeId=cfc210e42247a, content=不错 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:13:29 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062953, encodeId=009110629531e, content=非常值得一看，，特别有意思, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=LFRRP6YqrAia0BryFmv6ibnA&s=100&t=1555426989, createdBy=79c45230339, createdName=刘晓捷, createdTime=Fri Oct 22 14:49:27 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062735, encodeId=77601062e35a1, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Oct 21 21:17:57 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
    2021-10-22 刘晓捷

    非常值得一看，，特别有意思

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1074224, encodeId=cfc210e42247a, content=不错 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:13:29 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062953, encodeId=009110629531e, content=非常值得一看，，特别有意思, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=LFRRP6YqrAia0BryFmv6ibnA&s=100&t=1555426989, createdBy=79c45230339, createdName=刘晓捷, createdTime=Fri Oct 22 14:49:27 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062735, encodeId=77601062e35a1, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Oct 21 21:17:57 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
    2021-10-21 1207866fm50(暂无昵称)

    谢谢分享

    0

拓展阅读

2015 AHA科学声明：血管动脉硬化的研究的改善和标准化建议  

美国心脏协会(AHA,American Heart Association) · 2015-09-01

2018 JAS声明：恰当应用PCSK9抑制剂

日本动脉粥样硬化学会(JAS,Japan Atherosclerosis Society) · 2018-06-13